Project description
Novel treatment targets the origin of atrial fibrillation
Atrial fibrillation is a type of heart arrhythmia when rapid heart rate caused by chaotic electrical impulses in the atria result in rapid, uncoordinated contractions. This is a life-threatening condition with serious complications, such as stroke, and high worldwide prevalence. The most effective currently available treatment is cardiac ablation that specifically destroys heart tissue that triggers abnormal rhythm. However, this treatment requires highly trained personnel and carries significant risk of complications. AtriAN Medical has developed a novel treatment to target specifically the origin of the signal that causes atrial fibrillation and prevents the arrhythmia. This treatment promises high success rates and reduced risk of complications. The current EU-funded Neuron-AFib project will finalise testing and validation of the technology in order to meet regulatory requirements, followed by a safety and treatment efficacy clinical trial with broad patient enrolment.
Fields of science
Programme(s)
Funding Scheme
SME-2 - SME instrument phase 2Coordinator
H91W60E Galway
Ireland
See on map